This study aimed at develop and validate the procedure for collecting exhaled breath for drug testing. Patients receiving methadone maintenance treatment were recruited for the study. Methadone levels were measured using liquid chromatographyelectrospray-tandem mass spectrometry. The sampling device was based on a 47-mm C 18 filter and used under pressure to aid flow through the filter. The mouth was rinsed before sampling, and the device was constructed to protect against any saliva contamination. Methadone was present in breath samples before and after the daily intake of methadone. The mean (± SD) pre-dose level was found to be 135 ± 109 pg/min (n = 48, median 121). The exhaled methadone increased after dose intake. Saliva levels of methadone were high in comparison with exhaled breath levels. Saliva contamination was suspected in about 10% of the collected samples. Similar results were obtained using 1, 3, and 10 min sampling times. The inter-and intraindividual variability were found to be similar and in the order of 50%. Alternative sampling using XAD-2 beads and solid-phase microextraction fiber was found to be possible and enables sampling with low back pressure and with no need for pump assistance. The presented results confirm that breath testing is a new possibility for the detection of drugs of abuse.
Introduction
It has recently been proposed that testing for drugs of abuse can be performed by using sampling of exhaled breath (1) (2) (3) . Testing for drugs of abuse traditionally requires other specimens such as urine, blood, saliva, sweat, and hair. These specimens each have their specific features, advantages and disadvantages and are in many ways complementary to each other (4, 5) . In many instances, however, it is important to be able to collect a sample without need for specially trained personal (blood, hair) or facilities (toilet). Breath testing offer a new possibility in the testing for drugs of abuse since it might be developed to be as convenient as alcohol breath testing.
Very little is known at the moment about how drugs of abuse substances become carried in the exhaled breath. Human exhaled breath is known to contain a large number of substances, both volatile and non-volatile (6) (7) (8) . In our first study, amphetamine was selected as the main analyte because it is a substance known to be volatile as free base in laboratory work (1) . The demonstration that also the less volatile compound methadone is present in exhaled breath collected from patients receiving methadone maintenance treatment suggests that it is carried in the aerosol fraction of human breath. One way to sample this fraction has been by collecting exhaled breath condensate. This was shown also to work for methadone (3) . However, collection of exhaled breath condensate requires an instrument that cannot easily be transported and may not be an optimal solution for drugs of abuse testing.
The present study was aimed to further validate the sampling procedure used for methadone that is based on using a C 18 solid-phase extraction (SPE) filter. Furthermore, two alternative sampling techniques are being proposed and evaluated for the first time. metals basis) was from Sigma-Aldrich (St. Louis, MO). The Milli-Q water was of ultra-pure quality (> 18MΩ/cm) and prepared in-house. The 47-mm C 18 Empore disc and the 30-mg SPEC DAS SPE cartridge were from Varian (Palo Alto, CA). XAD-2 beads, with 20-60 mesh (Supelpak-2) and solid-phase microextraction (SPME) 85-μm polyacrylate fiber and fiber holder, were from Supelco Analytical (Bellefonte, PA).
Preparation of methadone solutions
The ampouled methadone and methadone-d 3 solutions were diluted to 100 µg/mL using methanol. These solutions were further diluted to suitable concentrations in 0.1% formic acid and stored at -18°C for a maximum of 1 year.
Study subjects
Patients undergoing methadone maintenance treatment (6 males, 1 female, aged 44-58 years) were recruited from the Methadone program in Stockholm (Beroendecentrum Stockholm). The patients were in steady-state and received supervised daily doses of methadone between 90 and 140 mg. The patients were subjected to regular control of compliance to treatment and any use of illicit drugs by urine drug testing. Ethical approval was obtained from the Stockholm Regional Ethics Committee (No. 2008/1347-31).
Sampling of exhaled breath on filter
Compounds present in the exhaled breath were collected for 1-10 min by suction through a 47-mm Empore C 18 disc using a membrane pump to assist the flow (about 300 mL/min). The subjects were asked to breathe more deeply than normal into an alcometer mouth piece (Palmenco AB, Stockholm, Sweden) mounted in the sampling device holding the Empore disc ( Figure 1 ). The mouth was always washed with water prior to the sampling. It was estimated that all the exhaled breath was collected through the filter during the sampling period. Following sampling, the Empore disc was dismantled using a tweezers and stored at -20°C. The sampling device was carefully cleaned between uses with 70% ethanol.
Following storage, the Empore disc was cut into 5 × 5-mm pieces using a scalpel and transferred to a 10-mL glass test- Figure 1 . Outline of the sampling device used to collect exhaled breath samples on an Empore C 18 disc. The subjects were asked to breathe more deeply than normal during the 10 min sampling time. The mouth was washed with water prior to sampling. A metal ring was inserted to separate incoming saliva from contaminating the filter. Figure 2 . Outline of the sampling devices used to collect exhaled breath samples on XAD-2 beads (A) and SPME fiber (B). The subjects were asked to breathe more deeply than normal during the 5-or 10-min sampling time. The mouth was washed with water prior to sampling. The XAD-2 beads were packed between two pieces of plastic foam. tube. A 25-µL volume of 100 ng/mL methadone-d 3 was added and mixed using a vortex mixer, 300 µL of 2-propanol was added (to wet the surface), mixed, and finally 5 mL of 20% methanol in ethyl acetate was added. This mixture was shaken for 1 h in a thermostatic bath at 37°C. Thereafter, the test-tube was centrifuged for 15 min at 3000 × g at 10°C, the supernatant transferred to a new 10 mL glass test-tube, and the extraction procedure repeated using 1 mL of 20% methanol in ethyl acetate. Finally, the two supernatants were combined, and 10 µL of 10% aqueous formic acid was added and evaporated to dryness under a stream of nitrogen at a temperature of 40°C. The dry residue was dissolved in 100 µL of 50% methanol in ethyl acetate.
Standards for quantification were prepared from fortified blank Empore discs. These were prepared by using solutions containing 20 or 300 ng/mL of methadone corresponding to 6-900 pg/disc. After drying, the discs were prepared for analysis as described. Calibration curves were constructed using linear regression analysis with weighting factor 1/x.
Sampling of exhaled breath on XAD-2 beads
Before use the XAD-2 beads was washed and activated by shaking in methanol for 3 h and drying at 180°C under nitrogen flow. The activated XAD-2 was stored under dryness. The exhaled breath was passed through a bed of XAD-2 beads using a device shown in Figure 2A . The diameter was 10 mm, three different resin bed lengths were used (5, 10, and 15 mm), and the sampling time was 3 min. The sampling was performed without support of pumping. Following sampling the XAD-2 beads was collected and stored in plastic test-tubes at -20°C.
Following storage, the XAD-2 beads were extracted by adding 0.3 mL 2-propanol, 4 mL methanol, and 20 µL of 20 ng/mL methadone-d 3 in methanol. The slurry was transferred to an activated (by 1 mL methanol and 1 mL water) 30-mg SPEC DAS cartridge, and the eluate was collected in a glass test-tube. Four subsequent 0.5-mL aliquots of methanol were added to the XAD-2 bed while avoiding drying of the bed. All fractions were collected in the glass test-tube. Following addition of 10 µL of 10% aqueous formic acid, the eluate was evaporated to dryness under a stream of nitrogen at a temperature of 40°C. The dry residue was dissolved in 100 µL of methanol.
Standards for quantification were prepared by fortifying XAD-2 beads (0.6 g) with methadone in methanol solution (100-2000 pg/sample) followed by drying.
Influence from matrix was studied in an infusion experiment. A prepared blank extract from XAD-2 beads was injected while infusing methadone post-column. The infusion rate was 10 µL/min, and the solution was 0.5 µg/mL of methadone in 50% methanol in 0.1% formic acid.
Sampling of exhaled breath on SPME fiber
The SPME fiber was activated by holding it in a gas chromatograph injector at 200°C for 60 min. The activated fiber was then kept in a capped glass test tube. The exhaled breath was passed by an SPME 85-μm polyacrylate fiber mounted opposite the air flow using a device shown in Figure 2B . The air stream was focused by a conical design with a 5-mm exit hole towards the SPME fiber situated 10 mm from the hole. The sampling time was 10 min. Following sampling, the fiber was dismantled and placed in a conical 0.3-mL autosampler vial containing 0.3 mL of methanol. The fiber tip was kept in the methanol for 5 min while ultrasound was applied, and then the methanol was stored at -20°C. Following storage, the methanol was dried under nitrogen after adding 10 µL of 10% formic acid in methanol and 20 µL of 20 ng/mL methadone-d 3 in methanol. The residue was redissolved in 100 µL of 50% (v/v) methanol in ethyl acetate.
Standards for quantification were prepared directly in methanol and ranged between 5 and 50 pg/sample.
Mass spectrometry (MS) analysis system 1
A 3-μL aliquot was subjected to analysis by selected reaction monitoring (SRM) ultra-performance liquid chromatography-(UPLC)-MS-MS (Waters Quattro Premier XE, Waters, Milford, MA). Details were previously published (2).
MS analysis system 2
A 10-μL aliquot was subjected to analysis by SRM LC-MS-MS (Sciex API 2000). The chromatographic system was an XTerra C 18 column (50 mm × 2.1 mm, 3.5-μm particle size) with an XTerra MS C 18 guard column (10 mm × 2.1 mm, 3.5-μm particle size, Waters), with mobile phase A = 0.1% formic acid and B = acetonitrile with 0.1% formic acid. The mobile phase was 85% A for 0.2 min, followed by a linear gradient from 15% B to 100% B to 2.5 min and kept at 100% B until 3.4 min. The equilibration time between injections was about 2.5 min (85% A). The flow rate was 0.425 mL/min.
Two product ions from the protonated molecules were monitored for methadone (m/z 310 → 265; 310 → 105) and one for methadone-d 3 (m/z 313 → 268). This was done by SRM in the positive electrospray mode with a 100 ms dwell time for each channel. Other instrumental settings were as follows: declustering potential, 14; curtain gas, 20 psig; collision gas (N 2 ), 10 psig; and ion source temperature 300°C. The minimum detectable amount (signal-to-noise ratio = 3) injected on column was about~1 pg.
Quantification of methadone in plasma
Venous blood was withdrawn in EDTA vacutainer tubes and plasma was prepared by centrifugation. Plasma levels of methadone were determined by an in-house routine method based on LC-electrospray-MS operating in positive selected ion monitoring mode. Plasma proteins were precipitated with acetonitrile (4:1, v/v) containing methadone-d 3 . The chromatographic system was a Phenomenex Luna C 18 column (50 mm × 2 mm, 2.5-μm particle size, Phenomenex, Torrance, CA), with mobile phase A = 25 mM formic acid, and mobile phase B = acetonitrile. The measuring range was 10-2000 ng/mL and the interassay coefficient of variation (CV) was < 10% as estimated from quality control samples.
Quantification of methadone in saliva
Saliva was sampled using the liquid-based Saliva Collection System (Greiner Bio-One GmbH, Kremsmünster, Austria) according to the manufacturer's instructions. Measured methadone concentrations in sampling solution were calculated to neat saliva concentration. Saliva concentrations were determined on an Olympus AU 680 using calibrators and controls from Greiner Bio-One according to their standard protocol.
A 100-μL aliquot of sampling solution was mixed with 200 μL methanol containing 80 ng racemic methadone-d 3 . After centrifugation, 200 μL of supernatant was mixed with 200 μL of 20 mM ammonium formate (pH 6.5), and 10 μL was injected into the UPLC-MS-MS system. Calibrators were prepared in 50% artificial saliva in Saliva Extraction Solution (SES, Greiner Bio-One) in concentrations of 15-1000 ng/mL for Rmethadone and S-methadone, respectively. The interassay coefficient of variation (CV) was < 5% as calculated from quality controls.
The chromatography system was a Chiral-AGP column (50 × 2 mm, 5-μm particle size) with a guard column (10 × 2 mm) obtained from Chiral Technologies Europe (Illkirch, France) with mobile phase 30% (v/v) methanol in 20 mM ammonium formate (pH 6.5).
Results
The sampling device using the Empore C 18 disc was modified to include separation of saliva fluid that could enter the device during sampling (Figure 1 ). This separation was designed to hinder any saliva fluid to reach the filter surface.
Two experiments were performed to study the amount of methadone in exhaled breath at three different times in the dose interval (Tables I and II ). In the first experiment using 10-min sampling time, there was a tendency for the excretion rate of methadone (measured as pg/min) to be lower before and 2-4 h after dose intake than that measured 12-35 min after dose intake, but the high (outlier) pre-dose value obtained for subject 1 hindered a firm conclusion (Table I) . A second experiment was therefore performed using shorter sampling time of 3 min and measurement of plasma and saliva levels (Table II) . Also in this experiment, one patient displayed outlier results. In this case, it was observed that the patient coughed during the sampling periods. The excretion rate of methadone at the pre-dose sampling time appeared not to correlate with plasma levels (n = 4). Neither did saliva levels appear to correlate with exhaled breath levels (r 2 = -0.18), apart from the fact that both breath and saliva levels were elevated directly after dose intake.
The length of the breath sampling time was studied in a separate experiment (Table III) . Two values appeared to be outliers and was omitted when calculating mean values that were 142, 145, and 97 pg/min for sampling times of 1, 3, and 10 min, respectively. A representative chromatogram obtained at the MS  MS  2  120  142  291  492  58  197  2054  229  210  571  3  110  -41  458  56  409  9746  232  92  1244  4  100  404  7188  564  52  2014  978  233  1734  665  5  120  566  138  1443  36  2434  88275  219 failed 2299 * MS, missing samples.
shortest sampling time (1 min) is shown in Figure 3 . The amount of methadone collected during the 1-min sampling time was enough for providing convincing analytical data. The identification of methadone was based on a correct retention time (± 0.5%) and correct relative ratio between the two product ions (± 20%). In these previous experiments it was noted that the reproducibility of the sampling might be an important matter to study. An experiment with triplicate consecutive sampling of three patients was performed (Table IV) . Mean, intra-, and interindividual variability (CV) was calculated and were 54 pg/min ± 20 (SD), 62%, and 61%, respectively. Because of the high intraindividual variability, the experiment was repeated (Table V) with the following results: mean, 46 pg/min ± 15 (SD); intraindividual variability, 39%; and interindividual variability, 50%.
When taking all pre-dose determinations of exhaled methadone together, a mean value of 681 pg/min was obtained (n = 53) with an SD value of 1920 and median of 133. Five of these results were > 3800 and considered to be outliers (possible saliva contamination), and calculation of the remaining 48 values gave mean (± SD) of 135 ± 109 pg/min (median 121).
Two alternative sampling techniques were evaluated in order to find a sampling procedure not needing pumping assistance. The two devices were constructed as shown in Figure 2 . In the first, a tube holding XAD-2 beads was mounted in the manifold. Three different thicknesses of packing bed were tested (5, 10, and 15 mm) using four patients. All three thicknesses made it possible to blow breath air without any significant resistance. Using a sampling time of 5 min, the results showed that methadone was trapped on the XAD-2 beads. The mean excretion rate was 11 ± 7 pg/min (n = 10) as estimated after deleting a blank result and a result that was 454 pg/min. There was no tendency for the trapped amount of methadone to increase with a thicker bed, although the variability precludes any firm conclusion. It was observed that extracts from XAD-2 beads produced chromatograms with interfering peaks. A matrix effect experiment was therefore performed using a post-column infusion of methadone. No suppression or enhancement could be observed as compared with no matrix injection at or close to the retention time of methadone. The overall extraction recovery of methadone from XAD-2 beads was 95% (n = 2). The other alternative sampling procedure was using an SPME fiber. This was done on three patients with a sampling time of 10 min. The chromatogram obtained for one of these samples is shown in Figure 4 . Methadone was identified using criteria of retention time and product ion ratio. The amount of methadone trapped on the SPME fiber was < 1 pg/min. Chromatogram from the determination of methadone in exhaled breath by using the SPME fiber device. Identification using LC-MS-MS was based on the presence of compound with correct retention time and with correct relative abundance of the two product ions. 
Discussion
This study confirms that methadone is present in exhaled breath from patients undergoing methadone maintenance treatment. In addition, this was measured for the first time predose.
In sampling of exhaled breath contamination from the oral cavity is of general concern (9). In the two previous studies of methadone (2, 3) , exhaled breath was sampled closely after the daily dose intake making contamination from the oral cavity possible. This is also obvious from the relatively high levels of methadone present in saliva after dose intake (Table II) . In our first study of methadone, sampling was performed immediately (8-60 min) after dose intake, and the sampling device was not constructed to protect the sampling filter from saliva contamination. The observed levels were 10-fold higher than when sampling of exhaled breath condensate was performed with an Eco-Screen device (3) . This device has a built-in separation mechanism to prevent any saliva from entering the system. Because of this observation, the device used in our present work was constructed to include saliva protection ( Figure  1 ). However, the results at the first post-dose sampling time point (Tables I and II ) from this and the first study (2) are comparable, which supports the idea that no significant saliva contamination occurred. In addition, it has been documented by measuring amylase activity in exhaled breath condensate that saliva contamination is, at most, trivial (10) .
Other observations also support the conclusion that methadone is being carried in the exhaled breath. Washing of the oral cavity with water was always performed before sampling as a precaution. In the first study this was not done in a few cases, but that did not make any difference. In one case (number 4 in Table II ) it was noted that the patient coughed through the sampling procedure and this resulted in higher measured levels. It should also be noted that in no case was a methadone patient sampled without methadone being measurable.
A sampling time of 10 min was originally used in this work. The results from the present experiment showed that even a sampling time of 1 min is sufficient. Based on this information, a sampling time of 3 min was hence used which made sampling from patients much easier. To make the sampling even more convenient, it would be of great value to have a filter with less back-pressure so that the need for pumping might be eliminated.
Throughout this work a significant variability in measured concentrations was noted. It was therefore important to perform the study of reproducibility (Tables IV and V) . The interindividual variability of 50-61% is not surprising considering that plasma trough values of methadone are likely to range between 200 and 600 ng/mL in maintenance patients. The intraindividual variability component 39-62% indicates that the sampling procedure needs to be better understood and standardized. Further study into this is warranted. For example, it may not be the time of the sampling that should be used for calculating excretion rates. In the field of breath analysis, this is a universal problem (6, 8) .
Other sampling techniques exist for sampling of volatile analytes from air. The use of porous polymer adsorbents tubes is common in environmental air analysis. The dimensions of such products produce high back-pressure and were therefore modified in our device in order to eliminate the need for pumping. Although promising results were obtained, the amount of methadone trapped was lower than with the Empore C 18 disc. The XAD-2 beads were difficult to handle from a practical perspective. The Empore disc extracts were previously studied for matrix effects and found not to produce any influence (2) . Because chromatographic peaks were observed from extracted blank XAD-2, a possible matrix influence on methadone ionization was again studied, but was not found to occur. The experiment with the SPME fiber was based on the publication that volatile analytes can be trapped from air by this means, and the construction of the sampling device mimicked the published procedure (11) . Although the results were promising, the trapped amount was very low. Although it is still unknown how methadone is carried in exhaled breath, it may be assumed that aerosol particles in micrometer size will carry non-volatile substances (7, 12) . It is likely that this is the case for methadone, but further study is needed. A recent study on breath aerosol physiology has demonstrated that the airway reopening is important for the formation of exhaled particles (13) . This may be of significance for the previously mentioned intraindividual variability between samplings.
So far, methadone has been utilized as a study compound because samples are readily available from patients receiving maintenance treatment. It is critical at this point to investigate if drugs of abuse other than amphetamine, methamphetamine, and methadone are also present in exhaled breath. If this is the case, breath testing for drugs of abuse may develop into a clinically useful alternative to urine or other fluids, as patients participating in these studies reported that breath sampling was more convenient than urine collection.
